Summary & Overview
HCPCS Level II C9075: Injection, casimersen, 10 mg
HCPCS Level II code C9075 denotes a 10 mg injection of casimersen, a specialty pharmaceutical administered parenterally. As a drug-specific HCPCS code, it standardizes billing for casimersen injections across outpatient clinics and infusion centers nationwide. This matters nationally because drug-specific HCPCS codes are used for pricing, prior authorization, and claims reporting for high-cost specialty therapies.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, reimbursement benchmarks where available, and the clinical context for casimersen administration. The content also outlines typical sites of service and expected billing considerations tied to a drug injection service line.
The publication provides concise benchmarks and policy context relevant to billing and claims processing for HCPCS Level II code C9075, notes common administrative practices for injectable specialty drugs, and identifies gaps where specific payer policy or coding detail is not provided. Data not available in the input will be identified as such within detailed sections.
Billing Code Overview
HCPCS Level II code C9075 represents Injection, casimersen, 10 mg. The service is a pharmaceutical injection of casimersen supplied in 10 mg units. Typical site of service for this code is a clinic or outpatient infusion/injection center, where parenteral administration of specialty medications is performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adolescent or adult with Duchenne muscular dystrophy (DMD) who has a confirmed mutation amenable to exon 45 skipping and is being treated with casimersen as part of ongoing disease-modifying therapy. The clinical workflow includes a specialist neuromuscular or pediatric neurology clinic visit for evaluation of treatment candidacy, baseline functional testing (e.g., 6-minute walk test, timed function tests), baseline laboratory studies (including liver function tests and creatine kinase), and informed consent discussion. Prior to each administration, the provider documents current weight for dose calculation, reviews interval adverse events, and assesses recent laboratory results. Casimersen is supplied as a vial billed as C9075 per 10 mg and is administered by a qualified clinician or registered nurse by intravenous infusion or as per product labeling in an infusion center, hospital outpatient department, or ambulatory infusion suite. Post-infusion monitoring for infusion reactions and routine periodic liver testing occur per prescribing information. Billing includes the drug HCPCS C9075 with appropriate units based on the milligram dose, any applicable administration CPT codes, and clinically relevant modifiers for facility or payer-specific reporting and bundling considerations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |